What is Abcodia?
Abcodia is a specialized healthtech enterprise primarily recognized for the development and commercialization of the ROCA Test. This innovative blood-based diagnostic tool is engineered to assess ovarian cancer risk specifically for women over the age of 35 who carry BRCA1 or BRCA2 gene mutations. By providing a viable alternative to immediate preventative surgery, the ROCA Test facilitates ongoing clinical surveillance, allowing patients to manage their genetic risk profiles with greater precision. The company operates at the intersection of oncology and preventative medicine, leveraging deep clinical insights to address significant gaps in women's health. Currently, the firm maintains a presence within the UK healthcare infrastructure, including the NHS, while simultaneously expanding access through private clinical channels in Cardiff and London.
How much funding has Abcodia raised?
Abcodia has raised a total of $8.2M across 1 funding round:
Unspecified
$8.2M
Unspecified (2015): $8.2M with participation from Scottish Equity Partners, Cambridge Innovation Capital, UCL Business PLC, and Albion Ventures
Key Investors in Abcodia
Scottish Equity Partners
Scottish Equity Partners is a prominent growth equity firm that provides capital and strategic resources to technology scaleups, focusing on long-term sustainability and market leadership.
Cambridge Innovation Capital
Cambridge Innovation Capital is a venture capital firm that bridges the gap between academic research and commercial success, specifically targeting intellectual property-rich life science and technology ventures.
UCL Business PLC
UCLB serves as the commercialization arm of University College London, dedicated to translating pioneering academic research and medical innovations into viable market solutions.
What's next for Abcodia?
With the recent influx of capital, Abcodia is positioned to accelerate its strategic roadmap, focusing on the broader adoption of the ROCA Test across diverse clinical environments. The company is expected to prioritize the expansion of its surveillance network, potentially increasing its footprint within the NHS and private healthcare sectors. Furthermore, the firm will likely leverage this financial backing to enhance its research and development capabilities, ensuring that its diagnostic offerings remain at the forefront of genetic risk management. As the company transitions into its next phase of growth, the focus will remain on scaling operational efficiency and solidifying its reputation as a leader in oncology-focused diagnostic technology.
See full Abcodia company page
